ArticleBritish journal of cancer2001
Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer.
Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Article
- Article
- Genome-wide methylation profiling in granulosa lutein cells of women with polycystic ovary syndrome (PCOS).Molecular and cellular endocrinology · 2020Article
- Downregulation of hypermethylated in cancer-1 byCancer cell international · 2018Article
- KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients.Cancer biomarkers : section A of Disease markers · 2016Article
- HIC1 Expression Distinguishes Intestinal Carcinomas Sensitive to Chemotherapy.Translational oncology · 2016Article
- Expression of the tumor suppressor gene hypermethylated in cancer 1 in laryngeal carcinoma.Oncology letters · 2015Article
- Small activating RNA restores the activity of the tumor suppressor HIC-1 on breast cancer.PloS one · 2014Article
- The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1).The Journal of biological chemistry · 2012Article
- Loss of Hypermethylated in Cancer 1 (HIC1) in breast cancer cells contributes to stress-induced migration and invasion through β-2 adrenergic receptor (ADRB2) misregulation.The Journal of biological chemistry · 2012Article
- Zinc finger protein ZBTB20 expression is increased in hepatocellular carcinoma and associated with poor prognosis.BMC cancer · 2011Article
- CpG-island methylation study of liver fluke-related cholangiocarcinoma.British journal of cancer · 2011Article
- The important molecular markers on chromosome 17 and their clinical impact in breast cancer.International journal of molecular sciences · 2011Review
- Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.BMC cancer · 2010Article
- HIC1 regulates tumor cell responses to endocrine therapies.Molecular endocrinology (Baltimore, Md.) · 2009Article
- Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control.Oncogene · 2009Article
- HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors.The international journal of biochemistry & cell biology · 2009Review
- Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1.Oncogene · 2006Article
- Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection.Oncogene · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new cancer gene, HIC-1 (Hypermethylated in Cancer) telomeric to p53 on chromosome 17p may be of clinical importance in sporadic breast cancer. Regional DNA hypermethylation of 17p13.3 resulting in suppression of gene expression has been shown to precede 17p structural changes in human carcinogenesis. In addition, loss of heterozygosity studies have suggested clinically significant involvement of a gene on 17p13.3 associated with poor prognosis in breast cancer. Using RT-PCR analysis, we demonstrate that the MCF7 (wild type p53) cell line expressed HIC-1 transcripts but the MDAMB231 (mutant p53) cell line did not, suggesting loss of HIC-1 expression and p53 malfunction may be synergistic events in sporadic breast cancer. HIC-1 expression was examined using RT-PCR on RNA extracted from 50 primary untreated, human breast cancers and was detected in only 7/50 (14%) cancers. All seven patients with HIC-1 expression were alive without disease recurrence after 8 years follow-up and 5/7 had detectable p53 wild type mRNA expression. This suggests that retained HIC-1 expression may offer a survival advantage. However the seven cancers had 17p13.3 loss of heterozygosity (LOH; four patients), a feature previously associated with poor prognosis, or were homozygous (three patients) suggesting there may be two genes at 17p13.3 involved in breast carcinogenesis. Using a demethylating drug 5-aza-2'-deoxycytidine (DeoxyC), HIC-1 expression was restored in the MDAMB231 cells, also suggesting restoration of HIC-1 function by reversing HIC-1 hypermethylation may offer a therapeutic avenue in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.